PICO Portalanswers from OpenAlex & ORCID
Michel Delforge
ResearcherPublications, citations & collaboration network
Michel Delforge is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does Michel Delforge have?
PICO Portalindexed works
Michel Delforge has 333 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Michel Delforge have?
PICO Portalcitation count
Michel Delforge has 18,198 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of Michel Delforge?
PICO Portalh-index
Michel Delforge has an h-index of 56 in OpenAlex.
What is the i10-index of Michel Delforge?
PICO Portali10-index
Michel Delforge has an i10-index of 129 in OpenAlex.
What is the ORCID of Michel Delforge?
PICO Portalorcid
The ORCID for Michel Delforge is on the source record.
What is the OpenAlex record for Michel Delforge?
PICO Portalopenalex
The OpenAlex for Michel Delforge is on the source record.
What are the most-cited papers on Michel Delforge?
PICO Portalmost cited works
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi, Larry D. Anderson, Nina Shah, Deepu Madduri, Jesús G. Berdeja, Sagar Lonial, Noopur Raje, Yi Lin, David S. Siegel, Albert Oriol, Philippe Moreau, Ibrahim Yakoub‐Agha, Michel Delforge, Michèle Cavo, Hermann Einsele, Hartmut Goldschmidt, Katja Weisel, Alessandro Rambaldi, Donna Reece, Fabio Petrocca, Monica Massaro, Jamie N. Connarn, Shari M. Kaiser, Payal Patel, Liping Huang, Timothy Campbell, Kristen Hege, Jesús F. San Miguel
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
Philippe Moreau, Michel Attal, Cyrille Hulin, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Marie C. Béné, Annemiek Broijl, Hélène Caillon, Denis Caillot, Jill Corre, Michel Delforge, Thomas Dejoie, Chantal Doyen, Thierry Façon, Cécile Sonntag, Jean Fontan, Laurent Garderet, Kon‐Siong G. Jie, Lionel Karlin, Frédérique Kuhnowski, Jérôme Lambert, Xavier Leleu, Pascal Lenain, Margaret Macro, Claire Mathiot, Frédérique Orsini‐Piocelle, Aurore Perrot, Anne‐Marie Stoppa, Niels W.C.J. van de Donk, Soraya Wuillème, Sonja Zweegman, Brigitte Kolb, Cyrille Touzeau, Murielle Roussel, Mourad Tiab, Jean‐Pierre Marolleau, Nathalie Meuleman, Marie‐Christiane Vekemans, Matthijs Westerman, Saskia K. Klein, Mark‐David Levin, Jean Paul Fermand, Martine Escoffre‐Barbe, Jean‐Richard Eveillard, Réda Garidi, Tahamtan Ahmadi, Sen Hong Zhuang, Christopher Chiu, Lixia Pei, Carla de Boer, Elena Smith, William Deraedt, Tobias Kampfenkel, Jordan M. Schecter, Jessica Vermeulen, Hervé Avet‐Loiseau, Pieter Sonneveld
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Paula Rodríguez‐Otero, Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel, Michèle Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Luciano J. Costa, Ravi Vij, Nizar J. Bahlis, Philippe Moreau, Scott R. Solomon, Michel Delforge, Jesús G. Berdeja, Anna Truppel-Hartmann, Zhihong Yang, Linda Favre‐Kontula, Fan Wu, Julia Piasecki, Mark Cook, Sergio Giralt
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Pieter Sonneveld, Meletios Α. Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksaç, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michèle Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W.C.J. van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda, Laura Rosiñol, Michel Delforge, Wilfried Roeloffzen, Tobias Silzle, Annette Juul Vangsted, Hermann Einsele, Andrew Spencer, Roman Hájek, Artur Jurczyszyn, Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M.J. van Brummelen, Véronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodríguez‐Otero, Joan Bladé, Philippe Moreau
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial
Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Marie C. Béné, Sonja Zweegman, Hélène Caillon, Denis Caillot, Jill Corre, Michel Delforge, Thomas Dejoie, Chantal Doyen, Thierry Façon, Cécile Sonntag, Jean Fontan, Mohamad Mohty, Kon‐Siong G. Jie, Lionel Karlin, Frédérique Kuhnowski, Jérôme Lambert, Xavier Leleu, Margaret Macro, Frédérique Orsini-Piocelle, Murielle Roussel, Anne‐Marie Stoppa, Niels W.C.J. van de Donk, Soraya Wuillème, Annemiek Broijl, Cyrille Touzeau, Mourad Tiab, Jean‐Pierre Marolleau, Nathalie Meuleman, Marie‐Christiane Vekemans, Matthijs Westerman, Saskia K. Klein, Mark‐David Levin, Fritz Offner, Martine Escoffre‐Barbe, Jean‐Richard Eveillard, Réda Garidi, Tahamtan Ahmadi, Maria Krevvata, Ke Zhang, Carla de Boer, Sanjay Vara, Tobias Kampfenkel, Véronique Vanquickelberghe, Jessica Vermeulen, Hervé Avet‐Loiseau, Pieter Sonneveld